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Abstract
Purpose Maintaining target hemoglobin (Hb) with mini-
mal variability is a challenge in hemodialysis (HD)
patients. The aim of this study is to compare the long- and
short-acting erythropoietin-stimulating agents such as Ar-
anesp and Eprex in achieving these targets.
Methods Randomized, prospective, open-labeled study of
24 weeks includes stable patients on HD [3 months,
age [18 years, and on Eprex for [3 months. Patients were
randomized into two groups: A-(Aranesp group):HD
patients on Eprex Q TIW or BIW were converted to Ar-
anesp Q weekly, by using the conversion factor of 200:1
and those on Eprex Q weekly to Aranesp Q 2 weeks;
B-(Eprex group):patients continued on Eprex treatment.
Hemoglobin target was set at (105–125 g/l). Primary end
points were percentage of patients achieving target Hb,
hemoglobin variability, and number of dose changes in
each group.
Results This study consisted of 139 HD patients: 72 in
the Aranesp and 67 in the Eprex—mean (SD) age 54 (16.2)
years, 77 (55 %) males. About 46 % were diabetic. Target
Hb achieved in 64.8 % of the Aranesp and 59.7 % in the
Eprex (p = 0.006). Hb variability was less frequent in the
Aranesp group (p = 0.2). Mean number of dose changes
was 1.3 (0.87) in the Aranesp and 1.9 (1.2) in the Eprex
(p \ 0.001). There was 1 vascular access thrombosis in the
Aranesp and 8 in the Eprex (p \ 0.001). There was no
difference in hospitalization and death number between the
2 groups.
Conclusions Aranesp Q weekly or every 2 weeks is more
efficient in achieving target Hb, with less dose changes and
minor vascular access complications.
Keywords Short  Long-acting ESAs  Target
hemoglobin  Hemoglobin variability  Hemodialysis
Introduction
The hormone erythropoietin is produced in the kidneys and
stimulates the bone marrow production of red blood cells.
Diseased kidneys do not release sufficient amounts of
erythropoietin hormone; anemia can result and it is universal
in end-stage renal disease (ESRD). Anemia secondary to
chronic kidney disease (CKD) is associated with increased
hospitalization and decreased survival [1, 2], increased bur-
den of cardiovascular disease [3, 4], and reduced quality of
life [5, 6]. With the growing prevalence of CKD [7, 8], new
approaches are required to improve the efficiency of anemia
management without increasing the workload of health care
staff. Erythropoiesis-stimulating agents (ESAs) have been
available for almost two decades and remain the central
strategy for the treatment for anemia in patients with CKD.
The use of ESAs in the management of renal anemia has
been shown to improve survival, reduce cardiovascular
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morbidity, and enhance quality of life [9, 10]. Recombinant
human erythropoietin (RHuEPO) such as Epo alfa has pro-
ven efficacy in treating anemia in CKD patients [10, 11].
Because of its relatively short half-lives [*24 h when
administered via the subcutaneous (SC) route] [12], this
agent is usually administered two or three times weekly.
However, multiple weekly injections are inconvenient for
patients and health care providers, particularly in the setting
of chronic disease. Darbepoetin alfa (Darbe alfa) is a longer-
acting ESA that contains two additional N-linked sialic acid-
containing carbohydrate chains compared with endogenous
erythropoietin and the standard rHuEPOs molecules [13–15],
its serum half-life is markedly longer than that of the rHu-
EPO, and it also has greater erythropoietic activity [12, 13,
16, 17]. Some studies have shown that the mean terminal
half-life of Darbe alfa is approximately 73 h following SC
administration in peritoneal dialysis (PD) patients and
patients with CKD not yet receiving dialysis (i.e., patients
with CKD stage 3 or 4) [17–19]. Thus, Darbe alfa may be
administered less frequently than standard rHuEPO (Epo)
and still maintains adequate serum concentrations to stimu-
late erythropoiesis with target Hb levels [16, 20]. Extended
administration intervals represent an opportunity to simplify
treatment and improve the efficiency of anemia management.
Direct comparison between short- and long-acting ESAs
in maintaining target Hb and stability is lacking. The aim
of the current study is to compare in hemodialysis patients,
between the long-acting ESA (Aranesp) and the short-
acting ESA (Eprex), in achieving target Hb and stability,




Hemodialysis patients on regular dialysis program at a
tertiary hospital. Inclusion criteria were as follows: stable
patients, on regular hemodialysis for at least 3 months,
age C18 years, and on Eprex treatment for more than
3 months. The exclusion criteria were as follows: the
presence of acute illness, chronic blood loss, hemoglobin-
opathy, or malignancy.
The study was conducted in accordance with the Decla-
ration of Helsinki and was approved by Al Ain Medical
District Research Ethics Committee (AAMDREC). All
patients gave written informed consent before participation.
Study design
This was a conversion, comparative, prospective, ran-
domized, and open-labeled study [All hemodialysis
patients dialyzed in center and fulfilled the study inclusion
criteria at the beginning of the study (November 2010)
were randomized and included].
The patients were randomized into 2 groups: Group A:
long-acting ESA (Aranesp) and Group B: short-acting ESA
(Eprex). Group A patients were converted from Eprex TIW
or BIW to once weekly of Aranesp and those on QW Eprex
to Q every 2 weeks of Aranesp. The recommended dose
conversion ratio on the European label (1 lg darbepoetin
alfa for 200 IU Epotein alfa) was used, while Group B
patients would be continued on the same Eprex regimen.
(During the study, there was freedom to adjust the doses in
both groups).
Efficacy was evaluated by target Hb that should be
110–120 g/l with a range of 105–125 g/l.
The primary end points of the study were evaluated by
the percentage of patients reaching the target Hb in each
group and the Hb stability in each group (Hb level, number
of interventions to achieve this).
The secondary end points were as follows: the treatment
cost in each group calculated as units/kg/week and mcg/kg/
week, factor of conversion from Eprex to Aranesp group
during the study (started at 200/1), number of hospital-
izations, deaths, and vascular access thrombosis during the
study in each group. There were 3 months of titration and
3 months of evaluation. Iron stores were maintained in
both groups to achieve Ferritin level C200 lg/l and
transferrin saturation C20 % (‘‘Appendix’’). Blood chem-
istry, bone profile, and iron profile were done on monthly
basis, complete blood count (CBC) once every 2 weeks
(Q2 W), and intact PTH (iPTH) every 3 months. Dialysis
adequacy was measured as online (KT/V) and urea
reduction ratio (URR).
Statistical analysis
To find a difference in mean Hb concentration C between
the two groups of 0.5 times the within-group standard
deviation, with a power of 80 % and a significance level of
5 %, a total of 63 patients per group is needed. One hun-
dred forty patients (who were fulfilling the study inclusion
criteria) were recruited.
Primary end points
1. Percentage of patients reaching the target Hb in each
group, there was 3 months of titration and 3 months of
evaluation. ‘‘Target Hb: was 105–125 g/l’’.
2. The Hb stability (variability) was assessed by
a. Summing the square of the difference between Hb
values and the previous Hb values (i.e., those
2 weeks earlier).
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b. Closeness (C) to target was assessed by summing
the square of the difference between observed Hb
values and 115.
c. Time on target in each group.
3. Number of dose changes in each group during study
duration.
Secondary end points
1. Cost calculated as units/kg/week and mcg/kg/week
during the study.
2. Factor of conversion from Eprex to Darbe group
during the study, we started at 200/1.
3. Vascular access thrombosis in each group during the
study period.
4. Number of hospitalizations and cause of hospitaliza-
tion, in each group during the study period.
5. Number of deaths and cause of death, in each group
during the study period.
Standard statistical tests such as independent sample t tests
for comparing continuous outcome measures between two
trial arms were used.
Results
The data of 139 hemodialysis patients were analyzed, 72
(52 %) were in Aranesp group and 67 (48 %) were in
Eprex group. The mean age was 54.4 (16.1) years, and
there were 77 (55.4 %) males. Diabetes mellitus was the
major cause of ESRD and encountered in 64 (45.7 %) of
the patients. The majority of patients 121 (86.5 %) had no
viral hepatitis while 15 patients (10.7 %) were HCV
positive and 4 (2.8 %) patients were HBV positive. The
vascular accesses AVF, TCC, and AVG were 97 (69.3 %),
23 (16.4 %), and 20 (14.3 %) in study cohort, respectively.
The mean hemodialysis vintage was 57.7 (51.2) months.
Table 1 shows the demographic data of both groups.
Table 2 illustrates the baseline and, during the study, dif-
ferent biological parameters in both groups. The target
hemoglobin (105–125 g/l) was achieved in 64.8 and
59.7 % in the Aranesp and Eprex groups, respectively, with
significance difference between the two groups
(p = 0.006); the details of the percentage of different Hb
levels are shown in Table 3. Hb variability is a measure of
both sum and mean of the square of the difference between
Hb values and the previous Hb values (i.e., those 2 weeks
earlier); closeness (C) which is the average of variability at
each month of follow-up among study groups was calcu-
lated in each group, as shown in Fig. 1. Time on target was
calculated as the average duration (in weeks) patients
maintained on target Hb (10.5–12.5 g/dl); in the Darbe and
Eprex groups, within the 6-month study duration, it was
16.8 and 15.3, respectively (p = 0.1). There was signifi-
cant difference in the number of dose changes during the
evaluation phase between the two groups, and it was 1.3
(0.87) in Darbe group and 2 (1.2) (p \ 0.01) in the Eprex
group, Fig. 2. The average weekly coast/kg was 1.4 USD in
Darbe group and 0.7 USD in the Epo group, Fig. 3.
Repeated-measure ANOVA for significant difference of
the Darbe conversion factor throughout the study visits
showed p \ 0.001. Repeated-measure ANOVA for signif-
icant difference of the Eprex dose throughout the visits
showed p = 0.606. There was 1 (1.4 %) vascular access
thrombosis in the Darbe group and 8 (12 %) in the Eprex
group (3 AVF, 3AVG, and 2 TC) (p \ 0.001). There were
25 (35 %) and 29 (43 %) hospitalizations in the Darbe and
Eprex groups, respectively (p = 0.56), and there were 2
deaths in each group during the study period (p = 0.99).
Discussion
The National Kidney Foundation Kidney Disease Outcome
Quality Initiative (KDOQI) recommends targeting Hb
between 11.0 and 12.0 gm/dl, but evidence suggests that
only 30 % of patients fall within this range at any point in
time [10]. Despite improvements, large observational
studies such as the Dialysis Outcomes and Practice Patterns
Study (DOPPS) indicate that anemia remains prevalent in
patients receiving dialysis; therefore, there is a need to
increase the proportions of patients achieving guideline Hb
targets [21]. Selection of the Hb target based on the
patient’s disease state, comorbidities, and other character-
istics has been an essential part of a treatment strategy [22].
However, the risks associated with high Hb targets in
recent studies [23, 24] prompted updates to the guidelines
to recommend a narrower Hb target: 110–120 g/l and not
exceeding 130 g/l for most patients and 100–120 g/l for
patients with type 2 diabetes mellitus (T2DM) avoiding
levels above 120 g/l, particularly for those at risk of stroke
[25]. In the current study, we have chosen the target of
110–120 g/l, with a margin of ±0.5 g/l, in line with the
current recommendations [24]. The results of this study
showed that both ESAs maintained the target Hb in almost
60 % of the patients, compared to the 40 % reported in
large dialysis US patients [26]. However, the results
illustrate the impact of the type of ESA used in maintaining
target Hb; there was a significant difference between the
percentages of patient achieving target Hb in the Darbe
group compared to those in Epo group, and this difference
was not demonstrated before. Hemoglobin variability
assessed by different statistical methods showed a tendency
of better Hb stability in the Darbe group compared to the
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Epo group, without reaching statistically significant dif-
ference between the two groups. Fluctuations in Hb levels
result in frequent under- and overshooting of targets [27,
28]. Evidence suggests that hemoglobin variability does
not only complicate maintenance of Hb within the target
range, but it is also independently associated with mortality
[29, 30]. On the other hand, stability of Hb in the target
level (110–120 g/l) is associated with lower 1-year mor-
tality risk in hemodialysis patients [29]. The number of
intervention for dose changes of the long-acting Darbe
group was significantly less compared to the Epo group.
Data show that longer dosing intervals may lead to less
variability in hemoglobin levels over time by producing
fewer peaks and troughs and thereby requiring fewer
Table 1 Demographics data of both groups
Aranesp Eprex Total p value
Study population 72 52 % 67 48 % 139 –
Male 31 43 % 46 69 % 77 (55 %) 0.002
Female 41 57 % 21 31 % 62 (45 %)
Age (years) 56.2 ±17.56 52.5 ±14.68 0.11
Nationality
UAE 35 48.6 % 26 39 % 61 (44 %) 0.24
Non-UAE 37 51.4 % 41 61 % 78 (56 %)
Etiology
DM 34 47 % 30 44 % 64 (46 %) 0.40
Unknown 22 31 % 20 29 % 42 (30 %)
Other 16 22 % 17 27 % 33 (24 %)
Duration of hemodialysis (months) 56.5 (60) 50 (42) 0.98
Hepatitis status
None 60 83 % 60 90 % 120 (86 %) 0.46
HCV ?ve 10 14 % 5 7 % 15 (11 %)
HBV ?ve 2 3 % 2 3 % 4 (3 %)
Vascular accessa
AVF 51 70 % 46 69 % 97 (70 %) 0.85
TC 12 17 % 10 15 % 22 (16 %)
AVG 9 13 % 11 16 % 20 (14 %)
Baseline dry weight (kg) 69 (18.3) 69 (17.5) 0.49
a AVF arteriovenous fistula, TC tunneled catheter, AVG arteriovenous graft
Table 2 Biological parameters in both groups
Laboratory Baseline Mean value during study period
Aranesp Eprex p value Aranesp Eprex p value
Ferritin 459.09 ±277.69 464.16 ±258.45 0.916 520.59 ±255.85 528.39 ±254.37 0.857
Transferrin saturation 30.31 ±11.62 32.47 ±16.6 0.393 33.30 ±9.23 32.26 ±9.22 0.505
Parathyroid hormone 50.5 ±38.4 43.87 ±43.5 0.881 52.93 ±53.74 42.20 ±33.31 0.179
Alkaline phosphatase 154.35 ±182.63 168.23 ±207.02 0.680 140.08 ±113.68 150.84 ±157.64 0.642
Albumin 33.69 ±3.54 34.16 ±3.53 0.433 33.82 ±3.22 34.10 ±3.24 0.608
Calcium (Ca) 2.26 ±0.15 2.23 ±0.15 0.136 2.30 ±0.11 2.26 ±0.14 0.055
Phosphate (PO4) 1.48 ±0.41 1.5 ±0.54 0.696 1.54 ±0.36 1.57 ±0.39 0.641
Sodium (N) 134.75 ±3.07 135.09 ±3.27 0.528 135.88 ±2.22 135.80 ±2.11 0.826
Potassium (K) 5.07 ±0.64 5.09 ±0.79 0.852 5.13 ±0.48 5.15 ±0.56 0.815
URRa 74.08 % ±11.94 74.86 % ±8.83 0.666 76.21 % ±5.85 75.56 % ±6.35 0.530
KT/Vb 1.29 ±0.21 1.33 ±0.20 0.355 1.32 ±0.19 1.32 ±0.17 0.982
a URR urea reduction ratio, a calculation measuring the dialysis efficiency (should be [66 %)
b KT/V calculation, measuring the dialysis efficiency (should be [1.3)
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dosage adjustments [31]. The recommended dose conver-
sion ratio on the European label (1 lg darbepoetin alfa for
200 IU Epotein alfa) was used in this study; there was a
steady increase in the conversion factor, with subsequent
decrease in the Darbe dose, during the study period from
200:1 at baseline to 350:1 at 6 months, with an average of
268:1 at the end of the study, with significant difference
from the baseline and the end (p \ 0.001). This conversion
ratio is higher than the average ratio reported in the meta-
analysis of 21 studies, with 16,378 patients of 217:1 and
that reported by the Canadian study of 169:1 [32]; this
difference in the conversion factor could be explained
by the different design of the studies (conversion vs.
straight), geographic area, quality of dialysis, and center-
related anemia management practice [33]. On the other
hand, the dose of Epo remained stable during the study
(p NS). The cost of Darbe was double that of Epo (1.4 vs.
0.7 USD/kg/week); however, several factors should be
taken into consideration in analyzing the cost. (1) Time
saving: preliminary results of an observational study indi-
cated that extending the administration interval from three
times weekly to once weekly (QW) was associated with
substantial time savings [34]. It was estimated that 350 h of
physician/nurse time per year could be saved in a center
with 50 dialysis patients. If administration intervals could
be successfully extended beyond QW for all patients, the
resulting time savings could enable health care providers to
spend more time focusing on other aspects of CKD man-
agement, including patient education, and to address other
modifiable risk factors, such as hypertension and mineral
balance. (2) The low conversion factor (200:1) with sub-
sequent high doses used as the start of the study could
explain in part the total high cost of Darbe; in other words,
if we would have used the ratio of (350:1) from the start of
the study, we would have saved 175 % of the cost. (3)
From the experience of using Darbe and Epo, in cancer
patients, taking into consideration the duration of clinical
benefit (DCB) that is 2–7 days in Epo and 7–21 days in
Table 3 Target Hb in each group
Total Hb measures in 6
visits and mid-months
Darbe Eprex p value
Hb level
Low (\10.5 g/dl) 91 11.3 % 128 16.8 % 0.006
Target (10.5–12.5 g/dl) 522 64.8 % 455 59.7 %
High ([12.5 g/dl) 193 23.9 % 179 23.5 %















Fig. 1 Mean monthly average of Hb variability and closeness C.*As
a measure of Hb variability by using both sum and mean of the square
of the difference between Hb values and the previous Hb values (i.e.,
those 2 weeks earlier) p = 0.08. **As a measure of closeness C to
target by using the square of the difference between observed Hb
values and 11.5, using nonparametric test (Mann–Whitney U)
p = 0.09
Fig. 2 Number of dose changes during the evaluation phase
(p \ 0.01). Mann–Whitney test for general association of the ESA
dose changing during evaluation phase between the two arms showed:
p \ 0.01
Fig. 3 Average weekly cost/kg (p \ 0.001). Mann–Whitney test for
general association of the ESA cost between the two arms showed:
p \ 0.001
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Darbe, one study showed, after accounting for DCB, that
the average weekly cost of darbepoetin alfa was signifi-
cantly lower than that of epoetin alfa ($619 vs. $940;
p \ 0.001) [35]. There was significant more vascular access
thrombosis in the Epo group compared to Darbe group (12
vs. 1.4 %) p \ 0.001, and vascular access thrombosis was
reported similar in Darbe and Epo groups (10 and 9 %,
respectively) in a previous study comparing the efficacy and
safety of Darbe to Epo [36]. The cause of difference in the
thrombosis of vascular access between the two groups in
our study is not well clear, and vascular access thrombosis
has been reported as a complication in dialysis patient
assigned to high Hb target [37]; in our study, the percentage
of patients with Hb [125 g/l was similar in both groups
(23.9, 23.3 %) and it cannot explain this phenomenon, but
one can speculate that the use of decreased doses of Darbe
during the study period could have a favorable impact on
the access thrombosis. All biological parameters evaluated
during the study were comparable between the two groups,
and there was no difference between the baseline and end of
the study parameters. There was no difference between the
two groups in terms of number of hospitalizations and
number of deaths.
Study limitations
1. The two groups were matched for several important
confounders; however, other residual confounders, like
the presence of inflammation, occult blood loss, mis-
sed dose injection, and others, could be there and not
matched between the two groups.
2. There was difference in gender between the two
groups; yet randomization was done by computer, but
patients were not stratified by gender; however, the
analysis of subgroups (male and female) did not show
any difference between males and females; in addition,
we did not find any literature supporting ESAs
response difference between males and females.
Conclusion
Darbepoetin alfa Q weekly or every 2 weeks is more effi-
cient in achieving target Hb, with less dose changes and Hb
variability, and much less vascular access complications.
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Appendix: Intravenous iron management protocol
• S. Iron, TIBC, and Ferritin to be checked every
3 months on all patients
• Target: T Sat between 20 and 50 %
• Aim where possible for Serum Ferritin 200–500.
If T Sat \20 % and/or Serum Ferritin \200 give iron
loading:
• Venofer 100 mg IV each dialysis for 10 doses
• Repeat iron profile 72 h after completion of iron
loading
• Repeat loading if needed or proceed to maintenance
dosage Venofer 100 mg IV every 2 weeks.
If T Sat 20–30 % and Ferritin \500
• Start Venofer 100 mg IV weekly 9 5 doses and then
maintenance of 100 mg IV every 2 weeks.
If T Sat 30–50 %
• Start or continue maintenance dose Venofer at 100 mg
IV every 2 weeks
• Continue checking iron profiles every 3-month titrates
accordingly.
For T Sat [ 50 % or
Ferritin [ 800
Hold iron (Fe overload)
For Ferritin [ 500 and T
Sat B20 % (inflammation)
Trial of 100 mg Venofer IV
weekly 9 10 doses and evaluated
response
• In case of holding iron, continue checking iron levels
every 3 months and treat accordingly
Note:
1. All patients with documented iron deficiency should
have stools tested for occult blood.
2. For patients with T Sat \30 % and S. Ferritin [500,
suggest inflammation and then trial of iron replace-
ment and evaluate response.
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